Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality ...

On Wednesday, Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality ...

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker.

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), Wednesday revealed positive results from its pharmacokinetics study of AD04 for the treatment of Alcohol Use Disorder in patients with a 5-HT3 genomic ...

On Wednesday, Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality, no food ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder. PE: Were there any specific patient demographics or ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), Wednesday revealed positive results from its pharmacokinetics study of AD04 for the treatment of Alcohol Use Disorder in patients with a 5-HT3 ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5.3 million, announced the ...